Estimating disease severity of Omicron and Delta SARS-CoV-2 infections-Reference-Cited by-同舟云学术

Estimating disease severity of Omicron and Delta SARS-CoV-2 infections

Published:2022-04-12 Issue:5 Volume:22 Page:267-269
ISSN:1474-1733
Container-title:Nature Reviews Immunology
language:en
Short-container-title:Nat Rev Immunol

Author:

Sigal Alex^ORCID,Milo Ron^ORCID,Jassat Waasila

Publisher

Springer Science and Business Media LLC

Subject

Energy Engineering and Power Technology,Fuel Technology

Link

https://www.nature.com/articles/s41577-022-00720-5.pdf

Reference10 articles.

1. Abdullah, F. et al. Decreased severity of disease during the first global Omicron variant Covid-19 outbreak in a large hospital in Tshwane, South Africa. Int. J. Infect. Dis. 116, 38–42 (2021).

2. Sigal, A. Milder disease with Omicron: is it the virus or the pre-existing immunity? Nat. Rev. Immunol. 22, 69–71 (2022).

3. New York State Department of Health. Pediatric COVID-19 update: January 7, 2022 https://www.health.ny.gov/press/releases/2022/docs/pediatric_covid-19_hospitalization_report.pdf (2022).

4. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 34 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1046853/technical-briefing-34-14-january-2022.pdf (2022).

5. Garret, N. et al. High rate of asymptomatic carriage associated with variant strain Omicron. Preprint at medRxiv https://doi.org/10.1101/2021.12.20.21268130 (2021).

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A two-variant model of SARS-COV-2 transmission: estimating the characteristics of a newly emerging strain;BMC Infectious Diseases;2024-09-09

2. Discovery of macrocyclic covalent inhibitors for severe acute respiratory syndrome coronavirus 2 3CL protease;Bioorganic & Medicinal Chemistry;2024-09

3. SARS-CoV-2 surveillance in a hospital and control of an outbreak on a geriatric ward using whole genome sequencing;Infection Prevention in Practice;2024-09

4. COVID-19 in adults: spectrum of illness and clinical presentation;COVID-19: An Update;2024-09-01

5. A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine;Vaccine;2024-09